DUBLIN–(BUSINESS WIRE)–The “Biopsy Devices – Global Market Insights, Competitive Landscape and Market Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.
The global biopsy devices market is anticipated to grow at a CAGR of 5.1% during the forecast period from 2022 to 2027.
The biopsy devices market is witnessing a positive growth owing to the various factors such as increasing prevalence of breast cancer, rise in geriatric population, rising incidence of lung cancer, and rising technological advancements with respect to the products offerings. Therefore, the market for biopsy devices is estimated to grow during the forecast period from 2022 to 2027.
Biopsy Devices Market Dynamics:
One of the main drivers of the biopsy devices market is the increasing prevalence of breast cancer. For instance, according to the World Health Organization (WHO) published data in the year 2021, in 2020, worldwide, breast cancer was diagnosed in 2.3 million women and it has been diagnosed in 7.8 million women in the previous five years as of the end of 2020.
Thus, biopsy devices are used to diagnose breast cancer and are used to assist the effective treatment for it. Therefore, the increasing prevalence of breast cancer boosts the biopsy devices demand, which surges the biopsy devices overall market forward over the forecast period (2022-2027).
Moreover, another key factor which is responsible for the growth of biopsy devices is the rise in geriatric population, as per the WHO published data in the year 2021, throughout the world, it was estimated that between years 2015-2050 the number of population aged 60 years and beyond will get doubled from 12-22% and will reach 2.1 billion by the year 2050.
Adding to it, by the year 2030, one out of every six person worldwide will age 60 years or above. The number of population aged 80 years or above is expected to get triple between the years 2020 and 2050 & will reach to 426 million population.
Further, as age increases the chances of suffering from disease also increases such as cancers, infections, inflammatory and autoimmune disorders. Therefore, rising geriatric population increases the demand for biopsy devices, this surge the biopsy devices overall market forward over the forecast period (2022-2027).
Therefore, the aforementioned factors boosts the biopsy devices demand, which surge the growth of overall biopsy devices market during the forecast period from 2022-2027.
Biopsy Devices Market Segment Analysis:
The Biopsy Devices Market is segmented by Product Type (Needles, Biopsy Systems, Forceps, Curettes, and Others), Application (Skin Biopsy, Bone Marrow Biopsy, Prostate Biopsy, Breast Biopsy, and Others), Imaging Technology (Ultrasound-Guided, MRI-Guided Biopsy, and Stereotactic-Guided Biopsy), End-user (Hospital, Diagnostic Centers, Imaging Centers, and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
North America is expected to dominate the overall Biopsy Devices Market:
Among all the regions, North America is expected to dominate the global biopsy devices market in the year 2021 and is expected to do the same during the forecast period from 2022-2027. Factors such as rising incidence of lung cancer and rising technological advancements with respect to the products offering of biopsy devices are expected to increase the demand of biopsy devices in the North America market.
According to the American Cancer Society published data in the year 2022, in United States, it is estimated that there will be 236,740 new cases of lung cancer in 2022. Thus, biopsy devices are used to diagnose lung cancer. Therefore, rising incidence of lung cancer increases the demand for biopsy devices thereby, propelling the growth of biopsy devices overall market.
Moreover, rising technological advancements with respect to the products offerings also drive the biopsy devices market growth.
Furthermore, aforementioned factors, provide a conductive growth environment for North American region in biopsy devices market.
Recent Developmental Activities in the Biopsy Devices:
In May 2022, Limaca Medical, a privately held company located in Israel devoted to enhancing endoscopic biopsy outcomes for patients with potentially life-threatening gastrointestinal tumors, gained FDA breakthrough device classification for its Precision GI endoscopic ultrasound biopsy device. Precision GI is deployed and operated through an instrument channel in the endoscope to biopsy a tumor.
In May 2022, Limaca Medical, a privately held company located in Israel devoted to enhancing endoscopic biopsy outcomes for patients with potentially life-threatening gastrointestinal tumors and HekaBio K.K., is a privately held healthcare company based in Tokyo, Japan announced that they have inked a strategic partnership agreement, whereby HekaBio is to distribute Limaca’s Precision-GIT Endoscopic Biopsy Device in Japan.
Companies Mentioned
Boston Scientific Corporation
Cardinal Health
Medtronic
BD
Cook
Devisor Medical Products Inc
B. Braun Melsungen AG
ARGON MEDICAL
OLYMPUS CORPORATION
FUJIFILM
INRAD Inc
Hologic Inc
C. R. Bard
Dr. Japan Co Ltd
Limaca-medical
Owlstone Medical Ltd
Zamar Care
KOELIS
ST. STONE MEDICAL DEVICES PVT LTD
Iscon Surgicals Ltd
For more information about this report visit https://www.researchandmarkets.com/r/kvsivq-devices?w=4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900